• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

484.03 -0.80 (-0.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
75 76 Next >
News headline image
2 Unstoppable Growth Stocks to Buy During a Market Crash ↗
October 15, 2025
Here are two smart ways to prepare for the next market downturn. 
Via The Motley Fool
Topics Government Stocks World Trade
News headline image
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today ↗
October 14, 2025
 
Via Benzinga
News headline image
4 Healthcare Stocks to Buy Now ↗
October 12, 2025
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity ↗
October 08, 2025
 
Via Benzinga
News headline image
The Smartest Growth Stock to Buy With $500 Right Now ↗
October 08, 2025
Vertex isn't your run-of-the-mill biotech stock. 
Via The Motley Fool
Topics Economy
News headline image
Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q2 Earnings?
October 08, 2025
Over the past six months, Vertex Pharmaceuticals’s stock price fell to $413.23. Shareholders have lost 12.5% of their capital, which is disappointing considering the S&P 500 has climbed by 34.7%. This... 
Via StockStory
Topics Stocks
News headline image
Worried About Tariffs? 2 Safe Haven Stocks to Buy on the Dip With $500 ↗
October 07, 2025
Tariffs aren't likely to weigh on growth at these companies. 
Via The Motley Fool
Topics Government Stocks World Trade
News headline image
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
October 06, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years ↗
October 06, 2025
 
Via Benzinga
News headline image
1 Healthcare Stock with Exciting Potential and 2 Facing Challenges
October 06, 2025
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
News headline image
2 Beaten-Down Stocks Primed for a Comeback ↗
October 05, 2025
The market is sleeping on these stocks, but you don't have to. 
Via The Motley Fool
News headline image
ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades' ↗
October 03, 2025
Jason Snipe likes ServiceNow (NOW), down 14% YTD. Morgan Stanley upgraded to Overweight. Shannon Saccocia chose iShares Core S&P Small-Cap ETF. Jim Lebenthal recommends Vertex Pharmaceuticals (VRTX). 
Via Benzinga
Topics ETFs Stocks
News headline image
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
October 04, 2025
As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for... 
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy
News headline image
Apple To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Thursday ↗
October 02, 2025
 
Via Benzinga
News headline image
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
October 02, 2025
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Healthcare Sector Defies Headwinds, Rallies on Wall Street Amidst Shutdown and Jobs Data
October 01, 2025
New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
October 01, 2025
 
Via Benzinga
News headline image
What Does the Market Think About Vertex Pharmaceuticals Inc? ↗
September 30, 2025
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
September 29, 2025
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
2 S&P 500 Stocks to Research Further and 1 We Avoid
September 29, 2025
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
News headline image
5 Top Stocks to Buy in October ↗
September 28, 2025
These five stocks are underperforming the S&P 500 in 2025, but have what it takes to reward investors over the long term. 
Via The Motley Fool
Topics Stocks
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
September 26, 2025
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗
September 26, 2025
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
News headline image
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗
September 25, 2025
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Assessing Vertex Pharmaceuticals: Insights From 15 Financial Analysts ↗
September 25, 2025
Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. 
Via Benzinga
News headline image
Vertex Announces Key Advancements Across Kidney Portfolio
September 25, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
This Chewy Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
September 25, 2025
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
My 3 Favorite Stocks to Buy Right Now ↗
September 25, 2025
Uncertainty is in the air. But these stocks inspire confidence. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Top GARP Stock ↗
September 24, 2025
Vertex Pharmaceuticals (VRTX) is a top GARP stock, offering strong revenue growth, high profitability, and a debt-free balance sheet at a reasonable valuation. 
Via Chartmill
News headline image
Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain
September 23, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap